Even the Sucampo 2013 Annual Report says Linzess is a better drug

[Anonymous]

On p 42 of their annual report, under the heading;Risks Related to Our Business and Industry


Our product, AMITIZA, faces competition from competitors’ products like linaclotide, which, in addition to other factors, could in certain circumstances lead to a significant reduction in royalty revenues and product sales. Our other product, RESCULA, faces competition from other competitors’ products, which, in addition to other factors, could lead to a significant reduction in product sales.


Our products, AMITIZA and RESCULA, face competition from competitors’ products. Specifically, AMITIZA faces competition from linaclotide which was recently approved for two of the three indications that AMITIZA has been approved in the U.S.
and for IBS-C in certain European countries. Its manufacturer is seeking approval in other markets for IBS-C that we currently
or intend to market AMITIZA. Linaclotide may be safer or more effective or more effectively marketed and sold than AMITIZA
is by our partners or by ourselves. Similarly, RESCULA faces competition from other competitors’ products which could be more effective, have better customer access or be more effectively marketed and sold. Alternatively, in the case of generic competition, including the generic availability of competitors’ branded products, they may be equally safe and effective products that are sold at a substantially lower price than our products. As a result, if we fail to maintain its competitive position, this could have a material adverse effect on its business, cash flow, results of operations, financial position and prospects.

 

[Anonymous]

Let me get this right

2013 - Takeda reps are BLUNTING the Linzess launch
2014 - Amitiza is forecasted for REDUCED sales


SMH..only at Takeda.

 

[Anonymous]

On p 42 of their annual report, under the heading;Risks Related to Our Business and Industry


Our product, AMITIZA, faces competition from competitors’ products like linaclotide, which, in addition to other factors, could in certain circumstances lead to a significant reduction in royalty revenues and product sales. Our other product, RESCULA, faces competition from other competitors’ products, which, in addition to other factors, could lead to a significant reduction in product sales.


Our products, AMITIZA and RESCULA, face competition from competitors’ products. Specifically, AMITIZA faces competition from linaclotide which was recently approved for two of the three indications that AMITIZA has been approved in the U.S.
and for IBS-C in certain European countries. Its manufacturer is seeking approval in other markets for IBS-C that we currently
or intend to market AMITIZA. Linaclotide may be safer or more effective or more effectively marketed and sold than AMITIZA
is by our partners or by ourselves. Similarly, RESCULA faces competition from other competitors’ products which could be more effective, have better customer access or be more effectively marketed and sold. Alternatively, in the case of generic competition, including the generic availability of competitors’ branded products, they may be equally safe and effective products that are sold at a substantially lower price than our products. As a result, if we fail to maintain its competitive position, this could have a material adverse effect on its business, cash flow, results of operations, financial position and prospects.

We got lucky Zelnorm was pulled and there was no competition for 7 years with Amitiza. Amitiza sales would align with Uloric's (about 100M less a year) had Zelnorm stayed on the market. I'm not surprised Sucampo is now trying to save ass with investors by coming out and telling them to expect revenue reductions with Amitiza due to Linzess.

Linaclotide may be safer

-all they have is diarrhea as a side effect, we have chest pain and headaches and nausea

or more effective

-we don't even have the indication for men in IBS and our MOA on IBS is really weak

or more effectively marketed and sold than AMITIZA
is by our partners or by ourselves.

-numbers speak for themselves, 1 year on the market and they've taken the TRX from us


Another example of another dog product from Takeda

 

[Anonymous]

Zelnorm had 16 million prescriptions in 2006 alone.

Amitiza has had just under 8 million prescriptions in 8 years.

#lookingdamngoodTakeda!

 

[Anonymous]

Zelnorm had 16 million prescriptions in 2006 alone.

Amitiza has had just under 8 million prescriptions in 8 years.

#lookingdamngoodTakeda!

Zelnorm has been removed from the market by the FDA
Zelnorm was withdrawn from the U.S. market on March 30, 2007. This medication may still be used in limited emergency situations.

Huge risk for heart attacks..

 

[Anonymous]

There is a site called Treato which collects web feedback on meds. 2370 reviewers of Amitiza give it a 4.5/5, while they give the Linzmess 3/5 for constipation
For IBS Amitiza gets 3.5 vs 2.5 for Linzmess.
Free info for what it is worth...

 

[Anonymous]

For what it's worth, about 61,000 practitioners have said the opposite. And that's after only 1 1/2 years.

 

[Anonymous]

For what it's worth, about 61,000 practitioners have said the opposite. And that's after only 1 1/2 years.

Owned!

 

[Anonymous]

For what it's worth, about 61,000 practitioners have said the opposite. And that's after only 1 1/2 years.

Hey Irondick

Nobody at Takeda cares about Amitiza, just drones and Forest slobs do. We are busy launching a new antidepressant and saving lives. I really don't care how well someone can take a shit. Congratulations on being a poop rep.